REGISTERED COMPANY NUMBER: CE004367 (England and Wales) REGISTERED CHARITY NUMBER: 1163211
Report of the Trustees and
Unaudited Financial Statements for the Year Ended 31st December 2020
for
European Parkinson's Disease Association
A4G LLP Kings Lodge London Road West Kingsdown Sevenoaks Kent TN15 6AR
European Parkinson's Disease Association
Contents of the Financial Statements for the Year Ended 31st December 2020
| Page | |
|---|---|
| Report of the Trustees | 1 to 5 |
| Independent Examiner's Report | 6 |
| Statement of Financial Activities | 7 |
| Statement of Financial Position | 8 |
| Statement of Cash Flows | 9 |
| Notes to the Statement of Cash Flows | 10 |
| Notes to the Financial Statements | 11 to 19 |
| Detailed Statement of Financial Activities | 20 to 22 |
European Parkinson's Disease Association
Report of the Trustees
for the Year Ended 31st December 2020
The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st December 2020. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
Introduction
2020 has been a very difficult year for the whole world, and in particular organisations working in the non-profit sector - including many EPDA member organisations - have been hit particularly hard by the COVID-19 pandemic. In spite of this, the EPDA has been able to adapt to the 'new normal' and achieve a series of accomplishments that, we believe, allow us to lay the foundations for a positive post-COVID-19 outlook.
In the past 12 months, we completed the process to substantially improve the EPDA's internal governance - reforming our Statutes (with the help and collaboration of our Members) and striving for increased transparency and democracy. We also acquired new member organisations and started a process to improve and boost the two-way communication with our members - the first step being an important survey to better understand our members' opinions, needs and challenges.
We have continued to develop our relationships with the treatment industry, securing a record number of funding partners going into 2021 and engaging in a number of win-win partnered projects that will benefit the Parkinson's community - in many cases leading to better treatment options for people living with the condition.
We continued the roll-out of our EU advocacy strategy and developed new EPDA strategic projects that are set to be carried out over the next four years.
Last but not least, we produced and delivered some impressive online resources (developed both independently and in partnership with the treatment industry) to provide support to the Parkinson's community during the COVID-19 lockdown periods.
The EPDA Team would like to thank the EPDA Board members for contributing with their knowledge, expertise and constant commitment to the positive results of the projects and activities detailed below.
Governance
Statutes:
o Amendments proposed and discussed in late 2019, voted by Members in early 2020 o Most proposed amends approved by a majority of the Members o Statutes changes ratified by the AGM in September 2020
o Amendment procedure to be finalised in 2021
Board:
o A new President and Vice-President elected o Three new full Board members (former observers) elected by the AGM o Three new Board observers appointed in 2020
Results
o Increased transparency and democracy o Smoother decision-making process and internal functioning o Improved expertise and representation in the Board
EPDA strategy
EPDA strategy reviewed by the EPDA Board at the end of 2020. Four strategic goals still fit for purpose:
a. To advocate for people with Parkinson's and their families to get the right information at the right time throughout their Parkinson's journey.
b. To strive for healthcare systems where people with Parkinson's receive early and appropriate treatment and individualised care.
c. To raise awareness of the complexity of Parkinson's and the impact it has on people's quality of life.
Page 1
European Parkinson's Disease Association
Report of the Trustees
for the Year Ended 31st December 2020
d. To support the global Parkinson's community in the search for a cure.
Three new strategic themes for the next three years:
a. Uniting Europe
b. Big data c. Research
Membership
Three new member organisations approved by the AGM in 2020 Member's survey
o Most member organisations are 'satisfied' with being EPDA members
o Most member organisations think the EPDA six-year strategy is fit for purpose
o Most member organisations think the current level of communication with the EPDA is 'good' or 'excellent'
Completion of a set of guidelines aimed at Parkinson's organisations in the event of a shortage of medicines (this idea was initiated as a result of the panel discussion at the 2019 Members' Meeting)
Involvement of 18 member organisations in the WPC clinical trials survey, and eight in the subsequent in-depth conference calls
Members' Meeting 2020 (virtual): participation and engagement from 20 members Member-specific activities being planned for 2021:
o Exclusive EPDA member virtual roundtable events
o EPDA membership grant scheme
Results
o Improved two-way communication between EPDA and MOs
o Development of EPDA-members partnered activities on topics that are fundamental for the European Parkinson's community
The EPDA would be delighted to hear about any initiatives from our members and partners that we could support, help advertise and promote, or advise on. If you need any help, please do get in touch and ask us!
Team improvements
A new Project Manager A new Communications Lead
Team restructuring: increasing hours and streamlining roles and tasks for all Team members
Results
o Improved expertise within the Team o Smoother internal functioning
EPDA exposure
High-profile international congresses:
o Continued partnership and collaboration with WPC 2022, which will lead to very exciting EPDA-led activities in 2021 and 2022
o MDS 2020: presentation of abstract about the EPDA-Air Liquide survey on the challenges of Parkinson's carers o INSIGHT into Parkinson's 2020: presentation on the EPDA survey on the challenges of Parkinson's carers
Medical/scientific journals:
o Advertisements and highlights from our website and the Parkinson's Disease Composite Scale (Oruen, touchNeurology)
Results
Increased knowledge and awareness of the EPDA and Parkinson's in the medical/scientific community Increased knowledge and awareness of the EPDA work in the Parkinson's community
Treatment industry collaboration
Funding (including work done in 2020 that has led to partnerships in 2021). Note: details below correct as at 8 February 2021
o Diamond partners: AbbVie (2020)
Page 2
European Parkinson's Disease Association
Report of the Trustees
for the Year Ended 31st December 2020
Boston Scientific (2020 and 2021) Britannia Pharmaceuticals (2021) Kyowa Kirin (2021) Sunovion (2020 and 2021) o Gold partners: Abbott (2021) Air Liquide (2020 and 2021) BIAL (2020 and 2021) Medtronic (2020 and 2021) Merz (2020 and 2021) Servier (2021) UCB (2020) o Silver partners: Biogen (2021) EverPharma (2020) Servier (2020) Theravance Biopharma (2021) UCB (2021) Zambon (2020 and 2021) o Tech partners: GE Healthcare (2020) Insightec (2020) o Other partners: Herantis (2020) Lundbeck (2020)
Partnered projects include:
o Abbott: development of a content campaign to raise awareness of the DBS options available to people with Parkinson's o AbbVie: EPDA Board members supporting AbbVie in the development of its Parkinson's research investigations o Air Liquide: carers' survey (dissemination of results in 2020 and 2021)
o Bial: collaboration with BIAL on the Keep it ON video awareness campaign, developing a series of awareness videos involving people with Parkinson's from five European countries o Bial: development of the Keep ON Moving! dual-task video exercise project in collaboration with BIAL
o Britannia Pharmaceuticals : development of a content campaign to raise awareness of the non-oral treatment options available to people with Parkinson's
o Herantis and TreatER: EU-funded project concluded and results published in a virtual webinar held in November 2020 o Kyowa Kirin: participation of the EPDA in an advisory panel on patient organisations engagement organised by Kyowa Kirin
o Medtronic: support of Medtronic's new Percept device launch, and review of World Parkinson's Day awareness materials o Merz: survey on sialorrhea in Parkinson's developed in collaboration with Merz (carried out in 2020, results expected in 2021)
o Servier: organisation of a workshop with people with Parkinson's, carers and advocates (preparation in 2020, virtual workshop to be held in 2021) in collaboration with Servier
o Sunovion: awareness communication campaign on Sunovion's clinical trial of sublingual apomorphine - developed in 2020, to be launched in early 2021
Results
Increased participation of the Parkinson's community (represented by the EPDA) in industry activities Ultimately, the development of better treatment, support and care solutions for people with Parkinson's
Research
TreatER project o Long-time collaboration with Herantis Pharma and lead academic universities o Started in 2017
o Results presented at a virtual scientific conference in November 2020
Sunovion CTH-302 trial
o Collaboration with treatment company and research institutions in six European countries
Page 3
European Parkinson's Disease Association
Report of the Trustees
for the Year Ended 31st December 2020
o Raising awareness of the clinical trial opportunities available to the Parkinson's community
Servier clinical trial design
o Involving the Parkinson's community in the guiding, planning, design and development of Servier's upcoming clinical trial o Organisation of a collaborative workshop with people with Parkinson's, carers and patient advocates
WPC clinical trials interest group
o Working with Parkinson's associations from around the world on surveys and conference calls in order to gather information about the barriers and opportunities for Parkinson's communities interested in getting involved in research
Results
Increased involvement of the Parkinson's community (represented by the EPDA, EPDA members and Parkinson's advocates) in the planning and design of treatment research More inclusive, effective and patient-friendly clinical trials
Ultimately, the development of better treatment solutions for people with Parkinson's
Advocacy
2020 was the year to prepare the ground for the EPDA's outreach for the next four years. A new EU came into power in 2020 and we have been assessing how they view health and indeed whether they know about Parkinson's. We are completing an in-depth political mapping of who's who in the Institutions directly but also indirectly influencing/impacting health policy. We have undertaken a decision-makers survey to assess their understanding of the disease and we have reached out to them to both introduce ourselves and to lay out our needs and asks.
We have developed a number of hooks for future advocacy campaigning in EU-Brussels around the role of carers as a follow-up to the EPDA/Air Liquide survey; around the role of pesticides and their impact on Parkinson's, and most recently on the EU's review of the pharmaceutical industry which will be a on-going issue for the year to come, looking at, for example, equal access to medicines, shortages of medicines, and many other key topics
The EPDA has been engaged closely with EFNA and played a role in developing their strategy for the Brain, Mind and Pain EP intergroup
We have developed the EU-Brussels Political Advocacy bi-monthly newsletter aimed at member organisations and other EPDA stakeholders
Ongoing support to the PD Avengers advocacy group throughout 2020 and into 2021
Results
Increased awareness of the complexity of Parkinson's and the impact it has on people's quality of life Ultimately, better policies and public interventions in support of people with Parkinson's, their families and carers
Resources and digital communication
Sleep and Parkinson's awareness campaign: initiated in Q4 2020 and to be launched in 2021 EPDA Exercise Cast: our own online video exercise series for people with Parkinson's (which led directly to the incredibly successful Keep ON Moving! exercise video series we created in collaboration with our partner, Bial) #BrainLifeGoals: educational video for HCPs focusing on cognitive-motor exercise programmes
EPDA website
o Nearly 370,000 users and more than 850,000 page views o Traffic from more than 200 countries
o High engagement to the About Parkinson's and Living Well sections
Parkinson's Life
o Parkinson's Life podcast awarded 'Best Global Audio Campaign of the Year' at the Global Content Awards 2020 o Nearly 270,000 users and 400,000 page views
EPDA strategic communications review - initiated in 2020, due to be finalised and implemented in 2021
Results
o Increased awareness of the complexity of Parkinson's and the impact it has on people's quality of life o Delivery of high-quality information and resources to the Parkinson's community
Page 4
European Parkinson's Disease Association
Report of the Trustees
for the Year Ended 31st December 2020
FINANCIAL REVIEW
Going concern
At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.
The Association's reserve policy is to hold reserves only to cover a period of 6 months administration costs. No additional reserves are intended to be held. Further analysis of restricted and unrestricted funds can be found in note 14.
STRUCTURE, GOVERNANCE AND MANAGEMENT
The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.
The trustees have had regard to the Charity Commission's guidance on public benefit.
REFERENCE AND ADMINISTRATIVE DETAILS Registered Company number
CE004367 (England and Wales)
Registered Charity number
1163211
Registered office
Kings Lodge London Road West Kingsdown Sevenoaks Kent TN15 6AR
Trustees
Mr K Onarheim (resigned 1.9.20) Ms M E Graham Ms S Lindvall (resigned 1.9.20) Ms V Clark Mr D J Lavender MBE Ms V A Buxton Ms P Gilmore J Domingos (appointed 1.9.20) C P Likar (appointed 1.9.20) T Shaish (appointed 1.9.20)
Independent Examiner
A4G LLP Kings Lodge London Road West Kingsdown Sevenoaks Kent TN15 6AR
Approved by order of the board of trustees on ............................................. and signed on its behalf by:
.................................................................... Ms V Clark - Trustee
Page 5
Independent Examiner's Report to the Trustees of European Parkinson's Disease Association
Independent examiner's report to the trustees of European Parkinson's Disease Association ('the Company')
I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st December 2020.
Responsibilities and basis of report
As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.
Independent examiner's statement
Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ACA which is one of the listed bodies.
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
-
accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
-
the accounts do not accord with those records; or
-
the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
-
the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Caroline Coleman ACA A4G LLP Kings Lodge London Road West Kingsdown Sevenoaks Kent TN15 6AR
Date: .............................................
Page 6
European Parkinson's Disease Association
Statement of Financial Activities
(Incorporating an Income and Expenditure Account) for the Year Ended 31st December 2020
| Unrestricted funds Notes £ INCOME AND ENDOWMENTS FROM Donations and legacies 4 28,283 Charitable activities 5 Member organisaton and board meetings - Other income - Investments 174 Publications - Project Income - Core Income 352,597 Total 381,054 EXPENDITURE ON Charitable activities 6 Member organisaton and board meetings 22,762 Advocacy communication and project development 213,615 Grant Funded projects 67,809 Support costs 186,018 Governance costs 1,000 Other 1,326 Total 492,530 Net gains/(losses) on investments 3,213 NET INCOME/(EXPENDITURE) (108,263) RECONCILIATION OF FUNDS Total funds brought forward 119,912 TOTAL FUNDS CARRIED FORWARD 11,649 |
Restricted funds £ - - - - - - 178,911 178,911 - 5,505 10,299 11,334 - - 27,138 (10,942) 140,831 182,767 323,598 |
2020 Total funds £ 28,283 - - 174 - - 531,508 559,965 22,762 219,120 78,108 197,352 1,000 1,326 519,668 (7,729) 32,568 302,679 335,247 |
2019 Total funds £ 26,626 22,374 1,895 313 6,774 52,557 255,664 366,203 40,223 72,356 100,025 129,098 1,000 - 342,702 (2,285) 21,216 281,463 302,679 |
|---|---|---|---|
The notes form part of these financial statements
Page 7
European Parkinson's Disease Association
Statement of Financial Position
31st December 2020
| Notes CURRENT ASSETS Debtors 11 Cash at bank and in hand CREDITORS Amounts falling due within one year 12 NET CURRENT ASSETS TOTAL ASSETS LESS CURRENT LIABILITIES NET ASSETS FUNDS 14 Unrestricted funds Restricted funds TOTAL FUNDS |
2020 £ 133,500 457,222 590,722 (255,475) 335,247 335,247 335,247 11,650 323,597 335,247 |
2019 £ 68,704 411,317 480,021 (177,342) 302,679 302,679 302,679 119,912 182,767 302,679 |
|---|---|---|
The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st December 2020.
The members have not required the company to obtain an audit of its financial statements for the year ended 31st December 2020 in accordance with Section 476 of the Companies Act 2006.
The trustees acknowledge their responsibilities for
(a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.
The financial statements were approved by the Board of Trustees and authorised for issue on ............................................. and were signed on its behalf by:
............................................. Ms V Clark - Trustee
............................................. Mr D J Lavender MBE - Trustee
The notes form part of these financial statements
Page 8
European Parkinson's Disease Association
Statement of Cash Flows
for the Year Ended 31st December 2020
| Notes Cash flows from operating activities Cash generated from operations 1 Net cash provided by operating activities Cash flows from investing activities Sale of fixed asset investments Net cash used in investing activities Change in cash and cash equivalents in the reporting period Cash and cash equivalents at the beginning of the reporting period Cash and cash equivalents at the end of the reporting period |
2020 £ 53,634 53,634 (7,729) (7,729) 45,905 411,317 457,222 |
2019 £ 28,365 28,365 (2,285) (2,285) 26,080 385,237 411,317 |
|---|---|---|
The notes form part of these financial statements
Page 9
European Parkinson's Disease Association
Notes to the Statement of Cash Flows
for the Year Ended 31st December 2020
| 1. | RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING | RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING | ACTIVITIES | |
|---|---|---|---|---|
| 2020 | 2019 | |||
| £ | £ | |||
| Net income for the reporting period (as per the Statement of | ||||
| Financial Activities) | 32,568 | 21,216 | ||
| Adjustments for: | ||||
| Losses on investments | 7,729 | 2,285 | ||
| (Increase)/decrease in debtors | (64,796) | 20,936 | ||
| Increase/(decrease) in creditors | 78,133 | (16,072) | ||
| Net cash provided by operations | 53,634 | 28,365 | ||
| 2. | ANALYSIS OF CHANGES IN NET FUNDS | |||
| At 1.1.20 | Cash flow | At 31.12.20 | ||
| £ | £ | £ | ||
| Net cash | ||||
| Cash at bank and in hand | 411,317 | 45,905 | 457,222 |
The notes form part of these financial statements
Page 10
European Parkinson's Disease Association
Notes to the Financial Statements
for the Year Ended 31st December 2020
1. CHARITY INFORMATION
European Parkinson's Disease Association is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.
2. ACCOUNTING POLICIES
Accounting convention
The accounts have been prepared in accordance with the charity's trust deed, the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and “Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)” (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.
The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.
The financial statements are prepared in sterling , which is the functional currency of the charity. Monetary a mounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.
Incoming resources
Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.
Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.
Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.
Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of discounts, VAT and other sales related taxes.
Charitable funds
Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.
Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.
Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.
Financial instruments
The charity has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.
continued...
Page 11
European Parkinson's Disease Association
Notes to the Financial Statements - continued
for the Year Ended 31st December 2020
2. ACCOUNTING POLICIES - continued
Financial instruments
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Basic financial liabilities
Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Derecognition of financial liabilities
Financial liabilities are derecognised when the charity’s contractual obligations expire or are discharged or cancelled.
Employee benefits
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in net income/(expenditure for the period.
Leases
Rentals payable under operating leases, including any lease incentives received, are charged as an expense on a straight line basis over the term of the relevant lease.
Irrecoverable vat
Irrecoverable VAT is charged against the expenditure heading for which it was incurred.
continued...
Page 12
European Parkinson's Disease Association
Notes to the Financial Statements - continued
for the Year Ended 31st December 2020
3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY
In the application of the charity’s accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
4. DONATIONS AND LEGACIES
| Members fees Donations 5. INCOME FROM CHARITABLE ACTIVITIES Member organisation meeting Other income Investments Publication income Project income Core income |
2020 £ 23,904 4,379 28,283 2020 £ - - 174 - - 531,508 531,682 |
2019 £ 24,408 2,218 26,626 2019 £ 22,374 1,895 313 6,774 52,557 255,664 339,577 |
|---|---|---|
6. CHARITABLE ACTIVITIES COSTS
| Member organisaton and board meetings Advocacy communication and project development Grant Funded projects Support costs Governance costs |
Direct Costs £ 22,762 215,978 78,108 68,988 - 385,836 |
Support costs (see note 7) £ - 3,142 - 128,364 1,000 132,506 |
Totals £ 22,762 219,120 78,108 197,352 1,000 518,342 |
|---|---|---|---|
continued...
Page 13
European Parkinson's Disease Association
Notes to the Financial Statements - continued
for the Year Ended 31st December 2020
7. SUPPORT COSTS
| Management £ Advocacy communication and project development 3,142 Support costs 5,637 Governance costs - 8,779 Support costs, included in the above, are as follows: Advocacy communication and project development £ Advertising 3,142 Fundraising - Wages - Bank charges - Financial administration - Accountancy fees - Bookkeeping costs - General expenditure - Administration costs - Independent examination costs - 3,142 |
Governance Finance Other costs £ £ £ - - - 65,095 57,632 - - - 1,000 65,095 57,632 1,000 2020 Support Governance Total costs costs activities £ £ £ - - 3,142 5,637 - 5,637 25,099 - 25,099 178 - 178 30,818 - 30,818 5,000 - 5,000 4,000 - 4,000 12,714 - 12,714 44,918 - 44,918 - 1,000 1,000 128,364 1,000 132,506 |
Totals £ 3,142 128,364 1,000 132,506 2019 Total activities £ - 14,926 8,693 - 15,326 4,760 - 13,062 8,436 1,000 66,203 |
|---|---|---|
Support costs, included in the above, are as follows:
8. TRUSTEES' REMUNERATION AND BENEFITS
Ms M E Graham received fees totalling £24,703 (2019: £16,747) in connection with her role as strategic advisor. The payments have been made in accordance with the charity's constitution and approved by the other trustees.
9. STAFF COSTS
| Wages and salaries | 2020 £ 25,099 25,099 |
2019 £ 8,693 8,693 |
|---|---|---|
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
The average monthly number of employees during the year was as follows:
| 2020 | 2019 | |
|---|---|---|
| Administration | 2 | 2 |
continued...
Page 14
European Parkinson's Disease Association
Notes to the Financial Statements - continued
for the Year Ended 31st December 2020
9. STAFF COSTS - continued
The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:
| £60,001 - £70,000 10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES Unrestricted funds £ INCOME AND ENDOWMENTS FROM Donations and legacies 26,628 Charitable activities Member organisaton and board meetings 22,374 Other income 1,895 Investments 313 Publications 6,774 Project Income 39,316 Core Income 174,249 Total 271,549 EXPENDITURE ON Charitable activities Member organisaton and board meetings 40,223 Advocacy communication and project development 72,356 Grant Funded projects 4,200 Support costs 126,880 Governance costs 1,000 Total 244,659 Net gains/(losses) on investments (2,285) NET INCOME/(EXPENDITURE) 24,605 RECONCILIATION OF FUNDS Total funds brought forward 95,309 TOTAL FUNDS CARRIED FORWARD 119,914 |
2020 1 Restricted funds £ (2) - - - - 13,241 81,415 94,654 - - 95,825 2,218 - 98,043 - (3,389) 186,154 182,765 |
2019 - Total funds £ 26,626 22,374 1,895 313 6,774 52,557 255,664 366,203 40,223 72,356 100,025 129,098 1,000 342,702 (2,285) 21,216 281,463 302,679 |
|---|---|---|
continued...
Page 15
European Parkinson's Disease Association
Notes to the Financial Statements - continued
| for the Year Ended 31st December 2020 11. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR Trade debtors Prepayments and accrued income 12. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR Trade creditors Social security and other taxes Net wages Pension Accruals and deferred income 13. ANALYSIS OF NET ASSETS BETWEEN FUNDS Unrestricted funds £ Current assets 267,125 Current liabilities (255,475) 11,650 |
Restricted funds £ 323,597 - 323,597 |
2020 £ 120,397 13,103 133,500 2020 £ 68,718 1,878 7,769 255 176,855 255,475 2020 Total funds £ 590,722 (255,475) 335,247 |
2019 £ 68,477 227 68,704 2019 £ 43,913 5,637 5,568 256 121,968 177,342 2019 Total funds £ 480,021 (177,342) 302,679 |
|---|---|---|---|
continued...
Page 16
European Parkinson's Disease Association
Notes to the Financial Statements - continued
for the Year Ended 31st December 2020
14. MOVEMENT IN FUNDS
| Unrestricted funds General fund Parkinson's Life Restricted funds PDCS Research/Clinical trials Parkinson's Information Data Collection Treat ER European Young Onset PD Advanced therapies AirLiquide Carers Project Brain Life Goals Bial HCP Info/Educational Materials Parkinson Sleep Project Parkinson's Games Tshipi's Art Exhibition WPC Barcelona 2020 TOTAL FUNDS |
Net movement At 1.1.20 in funds £ £ 124,112 (112,551) (4,200) 4,289 119,912 (108,262) 30,637 7,814 - 34,008 7,487 (7,487) 12,498 (131) 91,752 (4,046) 40,393 462 - 13,103 - 25,665 - 2,529 - 12,091 - 8,786 - 27,252 - 3,186 - 3,043 - 14,555 182,767 140,830 302,679 32,568 |
At 31.12.20 £ 11,561 89 11,650 38,451 34,008 - 12,367 87,706 40,855 13,103 25,665 2,529 12,091 8,786 27,252 3,186 3,043 14,555 323,597 335,247 |
|---|---|---|
continued...
Page 17
European Parkinson's Disease Association
Notes to the Financial Statements - continued
for the Year Ended 31st December 2020
14. MOVEMENT IN FUNDS - continued
Net movement in funds, included in the above are as follows:
| Unrestricted funds General fund Parkinson's Life Restricted funds PDCS Research/Clinical trials Parkinson's Information Data Collection Treat ER European Young Onset PD Advanced therapies AirLiquide Carers Project Brain Life Goals Bial HCP Info/Educational Materials Parkinson Sleep Project Parkinson's Games Tshipi's Art Exhibition WPC Barcelona 2020 TOTAL FUNDS |
Incoming resources £ 315,855 65,200 381,055 9,804 37,339 2,247 - - 2,693 13,103 29,731 2,705 15,721 9,035 29,418 4,260 3,361 19,493 178,910 559,965 |
Resources expended £ (424,721) (67,809) (492,530) (1,992) (3,331) (2,836) (131) - (2,231) - (4,066) (176) (3,630) (249) (2,166) (1,074) (318) (4,938) (27,138) (519,668) |
Gains and Movement losses in funds £ £ (3,685) (112,551) 6,898 4,289 3,213 (108,262) 2 7,814 - 34,008 (6,898) (7,487) - (131) (4,046) (4,046) - 462 - 13,103 - 25,665 - 2,529 - 12,091 - 8,786 - 27,252 - 3,186 - 3,043 - 14,555 (10,942) 140,830 (7,729) 32,568 |
|---|---|---|---|
Comparatives for movement in funds
| Unrestricted funds General fund Parkinson's Life Restricted funds PDCS Parkinson's Information Data Collection Treat ER European Young Onset PD TOTAL FUNDS |
Net movement At 1.1.19 in funds £ £ 95,309 28,803 - (4,200) 95,309 24,603 51,115 (20,478) 1,168 6,319 12,498 - 91,752 - 29,621 10,772 186,154 (3,387) 281,463 21,216 |
At 31.12.19 £ 124,112 (4,200) 119,912 30,637 7,487 12,498 91,752 40,393 182,767 302,679 |
|---|---|---|
continued...
Page 18
European Parkinson's Disease Association
Notes to the Financial Statements - continued
for the Year Ended 31st December 2020
14. MOVEMENT IN FUNDS - continued
Comparative net movement in funds, included in the above are as follows:
| Unrestricted funds General fund Parkinson's Life Restricted funds PDCS Parkinson's Information European Young Onset PD Advanced therapies AirLiquide Carers Project Parkinson’s Life TOTAL FUNDS |
Incoming resources £ 271,547 - 271,547 - 8,696 13,103 13,103 2,444 57,310 94,656 366,203 |
Resources expended £ (240,459) (4,200) (244,659) (20,478) (2,377) (2,331) (13,103) (2,444) (57,310) (98,043) (342,702) |
Gains and Movement losses in funds £ £ (2,285) 28,803 - (4,200) (2,285) 24,603 - (20,478) - 6,319 - 10,772 - - - - - - - (3,387) (2,285) 21,216 |
|---|---|---|---|
15. RELATED PARTY DISCLOSURES
There were no related party transactions for the year ended 31st December 2020.
Page 19
European Parkinson's Disease Association
| Detailed Statement of Financial Activities for the Year Ended 31st December 2020 INCOME AND ENDOWMENTS Donations and legacies Members fees Donations Charitable activities Member organisation meeting Publication income Investments Other income Core income Project income Total incoming resources EXPENDITURE Charitable activities Members meeting Administration Board PDG think tank Website Parkinson’s life Exhibitions Communications Social media Digital strategy Member organisation outreach GDPR PDCS Research/clinical trials Parkinson's info Data collection Global campaign Treat ER EYOPD Advocacy AirLiquide carers project Adviser Prevalence Merz (survey/HCP awareness) Medtronic Awareness projects HCP info/education materials Carried forward |
2020 £ 23,904 4,379 28,283 - - 174 - 531,508 - 531,682 559,965 7,246 22,105 - 9,690 72,009 1,539 14,185 6,629 6,083 10,273 540 2,946 3,331 2,836 131 - 8,220 2,231 161,744 4,066 16,194 302 3,017 309 249 355,875 |
2019 £ 24,408 2,218 26,626 22,374 6,774 313 1,895 255,664 52,557 339,577 366,203 38,052 31,991 2,171 7,922 58,392 12,999 10,050 20,470 10,228 11,934 1,076 28,089 1,550 2,748 1,812 2,404 250 2,380 1,877 28,557 1,547 - - - - 276,499 |
|---|---|---|
This page does not form part of the statutory financial statements
Page 20
European Parkinson's Disease Association
Detailed Statement of Financial Activities for the Year Ended 31st December 2020
| Charitable activities Brought forward Awareness campaigns Brain life goals Bial's Servier patient insights works Kyowa kirin Abbott AbbVie Boston affiliates Britannia (awareness) CMS EPDA industry meeting Industry partnered projects Medtronic partnered project NeuroPath EU project Parkinson sleep project Parkinson's games Sunovion research project Tshipi's art exhibition WPC Barcelona Other Rent Support costs Management Advertising Fundraising Finance Wages Bank charges Financial administration Accountancy fees Bookkeeping costs Other General expenditure Administration costs Governance costs Independent examination costs |
2020 £ 355,875 2,202 176 3,630 2,838 289 39 228 18 507 2,208 2,048 3,177 147 612 2,166 1,074 3,346 318 4,938 385,836 1,326 3,142 5,637 8,779 25,099 178 30,818 5,000 4,000 65,095 12,714 44,918 57,632 1,000 |
2019 £ 276,499 - - - - - - - - - - - - - - - - - - - 276,499 - - 14,926 14,926 8,693 - 15,326 4,760 - 28,779 13,062 8,436 21,498 1,000 |
|---|---|---|
This page does not form part of the statutory financial statements
Page 21
European Parkinson's Disease Association
| Detailed Statement of Financial Activities for the Year Ended 31st December 2020 Total resources expended Net income before gains and losses Realised recognised gains and losses Realised gains/(losses) on fixed asset investments Net income |
2020 £ 519,668 40,297 (7,729) 32,568 |
2019 £ 342,702 23,501 (2,285) 21,216 |
|---|---|---|
This page does not form part of the statutory financial statements
Page 22
European Parkinson's Disease Association
Statement of Financial Activities for
the Year Ended 31st December 2020
| INCOME AND ENDOWMENTS Donations Members Fees Donations Charitable Activities Member organisation meeting Publication Income Investments Other income Core income Project income Total incoming resources EXPENDITURE Charitable activities Members meeting Administration Board PDG think tank Website Parkinson’s life Exhibitions Communications Social Media Digital strategy Member organisation outreach GDPR PDCS Research/clinical trials Parkinson’s info Data collection Global campaign Treat ER EYOPD Advocacy AirLiquide carers project Adviser Prevalence Merz (survey/HCP awareness) Medtronic Awareness projects HCP info/education materials Carried forward |
2020(£) | 2020(£) | 2020(€) | 2020(€) | 2019(£) | 2019(£) | 2019(€) |
|---|---|---|---|---|---|---|---|
| 23,904 4,379 28,283 - - 174 - 531,508 - 531,682 559,965 7,246 22,105 - 9,690 72,009 1,539 14,185 6,629 6,083 10,273 540 2,946 3,331 2,836 131 - 8,220 2,231 161,744 4,066 16,194 302 3,017 309 249 355,875 |
26,709 4,893 31,602 - - 194 - 593,882 - 594,077 625,679 8,096 24,699 2,566 10,827 80,460 1,720 15,850 7,407 6,797 11,479 603 3,292 3,720 3,169 146 - 9,185 2,493 180,725 4,543 18,094 337 3,371 345 278 397,638 |
24,408 2,218 26,626 22,374 6,774 313 1,895 255,664 52,557 339,577 366,203 38,052 31,991 2,171 7,922 58,392 12,999 10,050 20,470 10,228 11,934 1,076 28,089 1,550 2,748 1,812 2,404 250 2,380 1,877 28,557 1,547 - - - - 276,499 |
This page does not form part of the statutory financial statements
Page 23
European Parkinson's Disease Association
Statement of Financial Activities for
the Year Ended 31st December 2020
| Charitable activities Brought forward Awareness campaigns Brain life goals Bial's Servier patient insights works Kyowa kirin Abbott AbbVie Boston affiliates Britannia (awareness) CMS EPDA industry meeting Industry partnered projects Medtronic partnered project NeuroPath EU project Parkinson sleep project Parkinson's games Sunovion research project Tshipi's art exhibition WPC Barcelona Other Rent Support costs Management Advertising Fundraising Finance Wages Bank charges Financial administration Accountancy fees Bookkeeping costs Other General expenditure Administration costs Governance costs Independent examination costs |
355,875 2,202 176 3.630 2,838 289 39 228 18 507 2,208 2,048 3,177 147 612 2,166 1,074 3,346 318 4,938 385,836 1,326 3,142 5,637 8,779 25,099 178 30,818 5,000 4,000 65,095 12,714 44,918 57,632 1,000 |
397,638 2,460 197 4,056 3,171 323 44 255 20 566 2,467 2,288 3,550 164 684 2,420 1,200 3,739 355 5,517 431,115 1,482 3,511 6,299 9,809 28,044 199 34,435 5,587 4,469 72,734 14,206 50,189 64,395 1,117 |
276,499 - - - - - - - - - - - - - - - - - - - 276,499 - - - - 8,693 - 15,326 4,760 - 28,779 13,062 8,436 21,498 1,000 |
326,753 - - - - - - - - - - - - - - - - - - - 326,753 - - - - 10,273 - 18,112 5,625 - 34,010 15,436 9,969 25,405 1,182 |
|||
|---|---|---|---|---|---|---|---|
This page does not form part of the statutory financial statements
Page 24
European Parkinson's Disease Association
Statement of Financial Activities for
the Year Ended 31st December 2020
| Total resources expended Net income before gains and losses Realised recognised gains and losses Realised gains/(losses) on fixed asset investments Net income |
519,668 40,297 (7,729) 32,568 |
580,653 45,026 (8,636) 36,390 |
342,702 23,501 (2,285) 21,216 |
404,988 27,772 (2,700) 25,072 |
||||
|---|---|---|---|---|---|---|---|---|
This page does not form part of the statutory financial statements
Page 25
European Parkinson's Disease Association
Statement of Financial Position for
the Year Ended 31st December 2020
| Statement of Financial Position for the Year Ended 31st December 2020 |
||||||||
|---|---|---|---|---|---|---|---|---|
| CURRENT ASSETS Debtors Cash at bank and in hand CREDITORS Amounts falling due within one year NET CURRENT ASSETS TOTAL ASSETS LESS CURRENT LIABILITIES NET ASSETS FUNDS Unrestricted funds Restricted funds TOTAL FUNDS |
2020(£) | 2020(€) | 2019(£) | 2019(€) | ||||
| 133,500 457,222 590,722 (255,475) 335,247 335,247 11,650 323,597 335,247 |
149,167 510,879 660,045 (285,456) 374,589 374,589 13,017 361,572 374,589 |
149,167 510,879 |
68,704 411,317 |
81,191 486,074 567,265 (209,574) 357,691 357,691 146,669 211,022 357,691 |
||||
| 374,589 13,017 361,572 |
||||||||
374,589 |
This page does not form part of the statutory financial statements
Page 26